{"prompt": "['- The PRODIGE partnership is mentioned in the title or after the authors. If the trial is a collaborative study, the', 'first association mentioned is the one that initiated the trial. The others are mentioned if they included at least', '5% of the patients, in order of their contribution.', '- For trials sponsored or managed by the FFCD, a member of the INSERM U1231 research unit will be the', 'second last author and will be mentioned as having \"equally contributed\" if this member is not the lead author', 'so that this work done by the INSERM is taken into consideration.', '- For trials sponsored or managed by UNICANCER, a representative of the sponsor will be included in the', 'authors.', '- The statistician will be named among the authors, generally after the third place. The statistician may be the', 'first or second author of a spin-off publication.', 'All contributors who do not appear among the authors are mentioned at the end of the article. Study managers', '(such as the project manager or data manager) are also mentioned.', 'One of these may occasionally be mentioned as an author if the PRODIGE coordination committee believes it to', 'be justified.', 'Partners are thanked, as are the patients and their families.', 'The authors and sponsor are sent a copy of the manuscript for review before submission to a journal. To', 'have their opinions taken into account, they undertake to reply within 15 working days, or 30 days in the', 'summer.', '6. Oral communications based on the trial results:', 'An investigator may, after obtaining the approval of the PRODIGE coordination committee and trial steering', 'committee, present in his or her own name all or part of the trial results in an oral presentation. The authors are', 'generally the same as in the written article, but the order of authorship may vary across articles and', 'communications, and also depending on the conference where the presentation is being made. In certain cases,', 'such as multidisciplinary studies or pathological, biological, endoscopic or imaging studies conducted alongside a', 'therapeutic trial, other authors may be chosen depending on their work. The name of the trial remains PRODIGE', 'XX (see \u00a7 3) and the other associations will be mentioned if necessary.', '7.', 'These rules must appear in the appendices of all PRODIGE trial protocols.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 119 de 123']['sham', \"PARTAGEONS PLUS QUE L'ASSURANCE\", \"ATTESTATION D'ASSURANCE\", 'RESPONSABILIT\u00c9 CIVILE', \"PROMOTEUR DE RECHERCHES INTERVENTIONNELLES relevant de l'article L 1121-1, 1\u00b0 du Code de\", 'la sant\u00e9 publique', \"Loi n 2012-300 du 5 mars 2012 et textes d'application subs\u00e9quent\", \"SOCI\u00c9T\u00c9 HOSPITALI\u00c8RE D'ASSURANCES MUTUELLES\", '18, rue Edouard Rochet - 69372 LYON CEDEX 08', 'Atteste que la', 'FEDERATION FRANCAISE DE', 'CANCEROLOGIE DIGESTIVE', 'FACULTE DE MEDECINE', 'BP 87900', '21079 DIJON', \"A souscrit sous le n\u00b0 137681 un contrat d'assurance de la Responsabilit\u00e9 Civile Promoteur d'une Recherche\", \"interventionnelle relevant de l'article L 1121-1, 1\u00b0 (Recherche interventionnelle comportant une intervention\", 'sur la personne non justifi\u00e9e par sa prise en charge habituelle) du Code de la sant\u00e9 publique-conforme aux', \"dispositions de l'article R 1121-4 du m\u00eame code, afin de couvrir les obligations mises \u00e0 leur charge en\", \"application de l'article L.1121-10 du m\u00eame Code.\", 'Le contrat couvre la recherche intitul\u00e9e :', 'PRODIGE 59 - FFCD 1707 - DURIGAST \" Etude de Phase II randomis\u00e9e \u00e9valuant l\\'efficacit\u00e9 du', 'FOLFIRI + durvalumab vs FOLFIRI + durvalumab + tremelimumab en deuxi\u00e8me ligne de traitement', 'chez des patients pr\u00e9sentant un ad\u00e9nocarcinome gastrique avanc\u00e9 ou gastro-oesophagien \" (Pr', 'David TOUGERON)', 'Dates pr\u00e9visionnelles de d\u00e9but et de fin de la recherche : Janvier 2019 - Mai 2023', \"Nombre pr\u00e9visionnel de personnes qu'il est pr\u00e9vu d'inclure : 105\", \"La garantie s'exerce pour les recherches r\u00e9alis\u00e9es exclusivement en France m\u00e9tropolitaine et dans\", \"les d\u00e9partements et territoires d' 'Outre-mer.\", \"La pr\u00e9sente attestation ne constitue toutefois qu'une pr\u00e9somption d'assurance \u00e0 la charge de la Soci\u00e9t\u00e9\", 'avant validation par les autorit\u00e9s comp\u00e9tentes.', 'Fait et Certifi\u00e9, \u00e0 LYON, 29/11/2018', 'July', 'Quentin GILLY', 'Souscription et vie des contrats', 'Direction \u00e9tablissements priv\u00e9s et professionnels de sant\u00e9', \"> SHAM Soci\u00e9t\u00e9 Hospitali\u00e8re d'Assurances Mutuelles\", \"Soci\u00e9t\u00e9 d'Assurance Mutuelle \u00e0 cotisations fixes.\", '18 rue \u00c9douard Rochet 69372 LYON Cedex 08', 'Entreprise r\u00e9gie par le code des assurances 779 860 881 RCS Lyon', 'T\u00e9l +33 Fax +33 (0)4 72 74 22 32 www.sham.fr', 'N\u00b0 TVA Intracommunautaire FR 79779860881 20041 01007 00333052038 15', 'APPENDIX 13: INSURANCE CERTIFICATE', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 120 de 123']\n\n###\n\n", "completion": "END"}